Newron Pharmaceuticals Launches Pivotal Phase III ENIGMA-TRS Program, Randomizing First Patients to Evaluate Evenamide as an Add-On Therapy in Treatment-Resistant Schizophrenia Newron Pharmaceuticals S.p.A. (SIX: NWRN, XETRA: NP5), a biopharmaceutical company specializing in therapies for diseases affecting the central and…
Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results, Advances Tecarfarin Clinical Development, and Strengthens Strategic Position in Anticoagulation Market Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company dedicated to developing next-generation anticoagulation therapies that address significant unmet needs in patient…
C2N Diagnostics Accelerates Global Expansion with Six New International Partnerships to Broaden Access to Alzheimer’s Blood Testing C2N Diagnostics, LLC (“C2N”), a specialty diagnostics company committed to its mission of delivering Clarity Through Innovation®, has taken a significant step toward…
Palleon Pharmaceuticals Initiates Phase 2 Clinical Trial of E-602 (HLX79) in Combination with HANLIKANG (Rituximab Biosimilar) for Patients with Active Glomerulonephritis Palleon Pharmaceuticals, a biotechnology company at the forefront of glyco-immunology drug development for autoimmune diseases and cancer, has announced…
U.S. Hospitals Achieve Significant Gains in Surgical Patient Outcomes Since 2019, AHA and Vizient Report Shows In a compelling new report released jointly by the American Hospital Association (AHA) and Vizient®, researchers have found that outcomes for hospitalized surgical patients…
United Therapeutics Launches $1 Billion Accelerated Share Repurchase Initiative, Underscoring Confidence in Long-Term Growth and Shareholder Value In a bold affirmation of its robust financial health, strategic vision, and shareholder-centric philosophy, United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation…
Arrowhead’s Subsidiary Visirna Transfers Greater China Rights to Plozasiran to Sanofi in Strategic $395 Million Deal Amid Regulatory Milestone in Hypertriglyceridemia In a move poised to reshape the therapeutic landscape for patients with severe lipid disorders in China, Arrowhead Pharmaceuticals,…
European Commission Greenlights AUCATZYL®: AGC Biologics Marks 10th Regulatory Approval with Autolus’ CAR-T Therapy AGC Biologics, a global contract development and manufacturing organization (CDMO) specializing in biologics and advanced therapies, has reached another significant milestone. On July 21, the European…
Bayer Raises Full-Year Outlook on Strong Pharma Performance, While Setting Aside €1.7 Billion for U.S. Litigation Risks Ahead of its scheduled second-quarter 2025 earnings release on August 6, Bayer AG has issued a significant update to its financial guidance for…
Actio Biosciences Receives FDA IND Clearance and Fast Track Designation for ABS-1230 in KCNT1-Related Epilepsy, Marking Major Advancement in Pediatric Precision Medicine Actio Biosciences, a clinical-stage biotechnology company pioneering novel therapies through the lens of genetics and precision medicine, has…
Novo Nordisk Ushers in New Era of Leadership as Maziar Mike Doustdar Is Named President and CEO, Effective August 7, 2025 Novo Nordisk, a global healthcare leader renowned for its innovations in diabetes and obesity treatment, has announced a major…
Avance Clinical Ushers in a New Era of Trial Excellence Through Strategic Digital Validation Partnership with ValGenesis In a strategic move set to redefine the landscape of clinical research quality management, Avance Clinical, a globally recognized Australian contract research organization…